We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.
Without Limits.
Announcement: Thryv Therapeutics to Participate in the 2024 Wells Fargo Virtual Private Biotech Symposium Read More.
Our Focus:
Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).
Breaking Barriers:
Isla Hutton
Long QT Type 3
We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome - In memory of Isla.
Together We Thryv
The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.
Together we share a vision to transform the lives of people with life-threatening conditions.
Follow our journey
